- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
ContraVir Pharmaceuticals to Present CRV431 Preclinical Data at the Anti-Fibrotic Drug Development Summit
EDISON, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of liver disease arising from chronic viral infection and non-alcoholic steatohepatitis, today announced that it will present a poster at the Anti-Fibrotic Drug Development (AAFD) Summit, being held in Cambridge, Massachusetts from November 27-29, 2018.
Daren Ure, PhD, ContraVir’s Director of Research and Development, will present preclinical data of the anti-fibrotic effects of CRV431, the Company’s cyclophilin inhibitor, on liver fibrosis in a model of nonalcoholic steatohepatitis.
Robert Foster, PharmD, PhD, Chief Executive Officer of ContraVir Pharmaceuticals, said, “Having previously demonstrated CRV431’s primarily antiviral mechanism of action, this presentation will review the anti-fibrotic and anti-cancer effects of CRV431, supporting CRV431’s potential to treat a broader range of liver disease.”
Presentation Details
CRV431, A Cyclophilin Inhibitor, Decreases Liver Fibrosis and Tumor Burden in a Mouse Model of Nonalcoholic Steatohepatitis (NASH)
Authors: Daren Ure1, Joseph Kuo2, Michael Bobardt2, Udayan Chatterji2, Philippe Gallay2, Daniel Trepanier1, Robert Foster1
1Contravir Pharmaceuticals, Edison, NJ and Edmonton, Alberta; 2Scripps Research Institute, La Jolla, CA
Date: November 28, 2018
Location: Hyatt Regency Cambridge
About CRV431
CRV431 is a non-immunosuppressive analog of cyclosporine A (CsA) whose primary biochemical action is inhibition of cyclophilin isomerase activity, playing a key role in protein folding. Other viruses such as HIV-1 and HCV, similarly use cyclophilin for their replication. In pre-clinical studies, CRV431 has shown potential in experimental models to complement current hepatitis B treatments by reducing multiple markers of infection including HBV DNA, HBsAg, HBx, HBeAg, and HBV uptake by cells. Studies have also demonstrated that CRV431 reduces the progression of fibrosis in an animal model and also reduces both the number and size of liver tumors in a hepatocellular carcinoma (HCC) model. |
|